Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43379
UPID:
WDR62_HUMAN
Alternative names:
-
Alternative UPACC:
O43379; Q63HP9; Q659D7; Q8NBF7; Q96AD9
Background:
WD repeat-containing protein 62 (WDR62) is pivotal in cerebral cortical development, influencing neuronal proliferation and migration. It is part of a complex mechanism involving CEP152, CDK5RAP2, and CEP63 that is crucial for centriole duplication, a process essential for cell division and development.
Therapeutic significance:
WDR62 is linked to Microcephaly 2, a disorder marked by significant brain development issues and intellectual disability. Understanding WDR62's role could lead to breakthroughs in treating or managing this condition, highlighting its therapeutic potential.